---

美国新泽西州林德赫斯特，2018年1月18日，消息 – 就专利上诉委员会最近宣布的关于爱美津制药有限公司挑战美国专利8,822,438 B2（专利拥有人强生肿瘤股份有限公司）双方专利复审（IPR2016-00286）的决定，爱美津总裁兼首席执行官John Lowry表示：“我们对于专利上诉委员会有关8,822,438专利所有权申请无效的决定感到十分高兴，这是Zytiga®（醋酸阿比特龙）唯一未到期的橙皮书专利。我们认为，专利上诉委员会的决定表明，法官仔细考量了各方提供的所有证据。该结果验证了我们的成为第一个针对8,822,438专利上诉申请的决定，爱美津将继续努力获得美国食品药品监督管理局批准其正在申请的简略新药申请，并尽快为患者提供醋酸阿比特龙的仿制药产品。
爱美津出席了来自McNeely Hare & War LLP律师事务所的 William Hare的双方专利复审（IPR2016-00286）听证会。
Zytiga®是强生所拥有的商标。

Lyndhurst NJ, USA, January 18, 2018 — In relation to the recently announced decision by the Patent Trial and Appeal Board (“PTAB”) on Amerigen Pharmaceuticals Limited’s inter partes review (IPR2016-00286), challenging U.S. Patent 8,822,438 B2 (owned by Janssen Oncology, Inc.), John Lowry, Amerigen’s President & CEO commented as follows “We are very pleased with the decision by the PTAB to invalidate all claims of the 8,822,438 patent, which is the sole unexpired Orange Book listed patent for Zytiga® (abiraterone acetate). We believe that the PTAB’s decision demonstrates that the judges carefully considered all of the available evidence presented by the parties. The outcome validates our decision to be the first to file a petition on the 8,822,438 patent and Amerigen will continue to work diligently to obtain FDA approval for its pending ANDA and bring a generic version of abiraterone acetate to patients as soon as possible.”
Amerigen was represented during the hearings on IPR2016-00286 by William Hare of McNeely Hare & War LLP.
Zytiga® is a trademark of Janssen.

---

---